Inventor · disambiguated record
Christine Rothe
Also filed as: ROTHE CHRISTINE
25 granted patents·8 pending applications·161 citations·filing 2003–2022
95Inventor score
Files withPIERIS PHARMACEUTICALS GMBH17SANOFI SA9BARDROFF MICHAEL2DAIICHI SANKYO CO LTD2HOFFMANN LA ROCHE2
Top patents by PatentIndex Score
33 records- 0195US9884898B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Feb 6, 2018·17 cites·20 claims
- 0295US7794719B2Anti-amyloid β antibodiesHOFFMANN LA ROCHE·Filed 2003·Granted Sep 14, 2010·77 cites·9 claims
- 0392US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0492US8329886B2Nucleic acid molecules encoding anti-amyloid beta antibodiesBARDROFF MICHAEL·Filed 2012·Granted Dec 11, 2012·22 cites·33 claims
- 0590US8216577B2Anti-Aβ antibodies and their useBARDROFF MICHAEL·Filed 2009·Granted Jul 10, 2012·14 cites·12 claims
- 0687US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 0785US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 0883US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 0982US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 1082US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 1180US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 1278US10329334B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Jun 25, 2019·1 cites·13 claims
- 1378US10118952B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Nov 6, 2018·1 cites·15 claims
- 1478US10072056B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 11, 2018·1 cites·18 claims
- 1578US10065998B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 4, 2018·1 cites·18 claims
- 1675US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 1775US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 1875US10316071B2Fusion moleculesSANOFI SA·Filed 2016·Granted Jun 11, 2019·2 cites·15 claims
- 1974US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 2072US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 2171US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 2271US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 2369US9150629B2Human tear lipocalins which bind PCSK9 and methods of use thereofPIERIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·56 claims
- 2466US2018371038A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2566US2018371037A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2666US2018346532A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2763US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 2859US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 2957US2013136747A1Anti-amyloid beta antibodies and their useHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
- 3050US9598476B2Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9DAIICHI SANKYO CO LTD·Filed 2015·Granted Mar 21, 2017·0 cites·51 claims
- 3150US2017173112A1Novel binding proteins for pcsk9DAIICHI SANKYO CO LTD·Filed 2017·Application pending·0 cites
- 3247US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 3336US2019010231A1Novel fusion polypeptide specific for lag-3 and pd-1PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christine Rothe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →